BeOne Medicines (NASDAQ:ONC) gains FDA approval for a new tablet version of Brukinsa, simplifying dosage for patients.

FDA Commissioner Marty Makary and CBER Director Vinay Prasad published an article in JAMA on Tuesday outlining the FDA’s ...

WEDNESDAY, June 11, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) says it plans to use artificial ...

Learn more about the generative AI technology that will be used at the Food and Drug Administration (FDA) to speed up reviews ...

The Food and Drug Administration (FDA) is looking to AI to solve the problem of lengthy approval processes, as the Trump ...

Federal regulators have launched a comprehensive review of the ingredients in baby formula — the first deep look at the ...

A recall of mislabeled cases of Dr. Pepper Zero Sugar has been upgraded amid a serious health risk, according to the US Food ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The tablet formulation of zanubrutinib (Brukinsa; BeOne) is now approved for all 5 indications across several hematological ...

The Breyers ice cream has been recalled because it may contain undeclared allergens, specifically nuts, which the FDA ...

Capricor Therapeutics' rating was downgraded amid FDA inspection risks, regulatory uncertainty, and potential delays in ...

Nine years after selling Medivation to Pfizer for $14 billion, David Hung, M.D., is going toe to toe with the New York ...